LifeStance Health Group Chief Technology Officer Sold Shares Worth Over $541K

LifeStance Health Group (LFST) filed a follow-on equity offering of 22.25 million shares. Analysts project $2.4B revenue and $146.1M earnings by 2029, with a fair value of $12.90. The offering may impact growth and dilution perspectives, while key risks include reimbursement pressures and competition.

LifeStance Health (LFST) announced a secondary offering of 22.25M shares by stockholders, with no proceeds to the company. LFST will repurchase 2M shares from the underwriter. Barclays is the sole underwriter. LFST stock traded between $4.77 and $13.15 in the past year, closing Tuesday at $12.80.

OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.

Lifestance Health Group (LFST) stock hit a 52-week high at $12.97, now trading at $13 with a $4.81B market cap. The stock surged 129.51% over the past year, driven by strong Q2 2026 earnings and raised full-year outlook. Revenue grew 26% to $435.35M, with adjusted EBITDA up 94% to $66M, according to the company.

LifeStance Health Group (LFST) reported Q2 2026 revenue of $435.35M and net income of $23.61M, reversing a year-ago net loss. The company completed a $97.19M share repurchase and authorized a new buyback up to $100M. Full-year 2026 revenue guidance was raised to $1.69B-$1.73B.

LifeStance Health Group (LFST) reported Q2 revenue of $435.4M, above estimates of $414.6M, and adjusted EPS of $0.11 vs $0.08. Adjusted EBITDA was $66.04M. The company raised full-year revenue guidance to $1.71B and EBITDA guidance to $225M midpoint, citing clinician productivity, specialty services growth, and digital workflow tools.